8-K: KALA BIO Settles $10.6M Debt, Issues Shares for Claims

KALA BIO announced the settlement of approximately $10.6 million in debt with Oxford Finance and resolved other claims by issuing 4.6 million common shares.

Summary

• KALA BIO, Inc. (the Company) settled approximately $10.6 million in debt obligations with Oxford Finance, LLC by making a $2 million payment.
• The Company entered into a settlement agreement with Baker Bros. Advisors LP, issuing 900,000 common shares to resolve claims related to participation rights.
• A voting agreement was established with Baker Bros., granting the Company an irrevocable proxy to vote the settlement shares and other specified shares in line with board recommendations for six months.
• The Company settled payment obligations for financial advisory services with LifeSci Capital LLC by issuing 2,200,000 common shares. This is in addition to a $420,000 cash private placement fee.
• A $600,000 debt owed to Delaware IR LLC for marketing and advertising services was settled by issuing 1,100,000 common shares, with a make-whole provision if net sale proceeds are less than the debt.
• An additional 400,000 common shares were issued to employees as material inducement to employment, approved by the Compensation Committee.
• In total, 4,600,000 common shares were issued in private, unregistered transactions on December 30, 2025, relying on Section 4(a)(2) exemptions.

Sentiment

Score: 6

Explanation: While the debt settlement is a positive step, the significant dilution from equity issuance and the explicit mention of attempting to avoid bankruptcy indicate ongoing financial challenges and uncertainty. The conditional nature of some settlements also adds a layer of risk.

Positives

• Successful settlement of approximately $10.6 million in debt obligations with Oxford Finance, LLC for a $2 million payment.
• Resolution of claims with Baker Bros. Advisors LP, LifeSci Capital LLC, and Delaware IR LLC through equity settlements.
• Removal of a "substantial overhang" on strategic flexibility, as stated by the CEO.
• Increased stockholders' equity due to debt settlement.

Negatives

• Significant dilution from the issuance of 4,600,000 common shares in private transactions.
• The Delaware IR settlement includes a make-whole mechanic, potentially requiring further compensation if share sale proceeds are insufficient.
• The settlements with Baker Bros. and LifeSci are conditional; if the Company enters bankruptcy within five years, the providers' waivers of claims are automatically rescinded, allowing them to seek the full amount owed.

Risks

• The conditional nature of the Baker Bros. and LifeSci settlements means that if the Company enters receivership or bankruptcy within five years, the providers' waivers of claims are rescinded, and they can seek the full amount originally owed.
• Potential for further dilution if the make-whole provision for Delaware IR LLC is triggered.
• The Company is actively seeking investors to acquire its assets to avoid bankruptcy, indicating ongoing financial distress.

Future Outlook

The Company is confident in its path forward after settling debt obligations and increasing stockholders' equity. However, the conditional nature of some settlements indicates an ongoing attempt to find investors to acquire assets to avoid bankruptcy.

Management Comments

• The successful completion of the Oxford settlement represents a watershed moment for KALA BIO.
• By settling the Company's debt obligations and increasing stockholders' equity, we have removed a substantial overhang that was constraining the Company's strategic flexibility.
• We are confident in our path forward.

Industry Context

This filing reflects a company undergoing significant financial restructuring, a common occurrence for smaller biotechnology or early-stage companies facing liquidity challenges or needing to clean up their balance sheet to attract new investment or avoid bankruptcy. The use of equity to settle debt is a typical strategy when cash is constrained.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The settlement agreements resolve "certain claims" and "payment obligations," which implies potential or actual disputes that are now settled.

Related Party Transactions

• The Baker Bros. settlement relates to participation rights under a securities purchase agreement with David Lazar (CEO) dated November 23, 2025, which could be considered a related party transaction.

Stakeholder Impact

• Shareholders: Significant dilution due to the issuance of 4,600,000 new common shares. Potential for increased share price volatility due to the make-whole provision and conditional settlements.
• Creditors (Oxford Finance): Debt obligations of $10.6 million fully satisfied and discharged with a $2 million payment.
• Creditors (Baker Bros., LifeSci, Delaware IR): Claims settled through equity, but with conditional terms for Baker Bros. and LifeSci that could revert if bankruptcy occurs. Delaware IR has a make-whole provision.
• Employees: 400,000 common shares granted as inducement to employment, potentially boosting morale and retention.

Next Steps

• Baker Bros. Advisors LP will vote their Proxy Shares in favor of all proposals recommended by the Board of Directors for six months from the Proxy Effective Date.
• The Company will use commercially reasonable efforts to execute the Settlement Agreement and undertake contemplated actions, and cause the Issued Shares to be issued in accordance with the Settlement Agreement.
• Providers (Baker Bros., LifeSci) have piggy-back registration rights to include their shares on new SEC registration statements.
• The Company continues its attempt to find investors to acquire its assets to avoid bankruptcy.

Key Dates

Recommendation

While the significant debt reduction with Oxford Finance is a positive, the substantial equity dilution and the explicit mention of the company trying to avoid bankruptcy indicate ongoing financial distress and high risk. The conditional nature of some settlements adds further uncertainty. Investors should hold to monitor the company's ability to secure new investment or asset acquisition and navigate its financial challenges, as the path forward remains precarious despite the recent settlements.

Keywords

KALA BIO, Debt Settlement, Equity Issuance, SEC Filing, 8-K, Oxford Finance, Baker Bros. Advisors, LifeSci Capital, Delaware IR, Common Stock, Dilution, Corporate Governance, Financial Advisory, Participation Rights, Bankruptcy Risk